Patents by Inventor Jeffrey A. Bluestone

Jeffrey A. Bluestone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12103958
    Abstract: The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: October 1, 2024
    Assignees: Pfizer Inc., The Regents of the University of California
    Inventors: Natasha Kay Crellin, Lauren Kate Ely, Jason Robles Reyes, Chia Chi Ho, Jeffrey A. Bluestone, Eleonora Trotta, Qizhi Tang
  • Publication number: 20240301403
    Abstract: This disclosure generally relates to high-throughput and modular methods and compositions for barcode-trackable cellular receptor design, manufacture, and measurement.
    Type: Application
    Filed: January 28, 2022
    Publication date: September 12, 2024
    Inventors: Daniel B. GOODMAN, Camillia S. AZIMI, Kole T. ROYBAL, Jeffrey A. BLUESTONE, Alexander MARSON
  • Publication number: 20240245733
    Abstract: Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.
    Type: Application
    Filed: February 7, 2024
    Publication date: July 25, 2024
    Inventors: Casey Ward, Qizhi TANG, Peter STOCK, Gaetano FALEO, Gopika NAIR, Matthias HEBROK, Wenhan CHANG, Thuy VO, Jeffrey A. BLUESTONE, Elenora DE KLERK
  • Patent number: 11951136
    Abstract: Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: April 9, 2024
    Assignees: The Regents of the University of California, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Casey Ward, Qizhi Tang, Peter Stock, Gaetano Faleo, Gopika Nair, Matthias Hebrok, Wenhan Chang, Thuy Vo, Jeffrey A. Bluestone, Eleonora De Klerk
  • Publication number: 20230381228
    Abstract: The present disclosure relates generally to regulatory T cells (Tregs) engineered to express a dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR). The engineered Tregs are suitable for use in immunotherapy regimens for autoimmune, inflammatory and degenerative diseases. In particular, the anti-DPP6 CAR expressing Tregs are suitable for treating or preventing autoimmune diseases of the pancreas or central nervous system.
    Type: Application
    Filed: October 29, 2021
    Publication date: November 30, 2023
    Applicants: The Regents of the University of California, Université Libre de Bruxelles, Vrije Universiteit Brussel
    Inventors: Qizhi TANG, Jeffrey A. BLUESTONE, Emilie RONIN, Decio L. EIZIRIK, Nick M. DEVOOGDT
  • Publication number: 20230340068
    Abstract: The present disclosure relates generally to the field of immuno-therapeutics, and particularly relates to novel chimeric polypeptides, e.g., chimeric antigen receptors (CARs) that include a transmembrane domain from CD28 and a hinge domain. In some cases, the hinge domain is capable of promoting dimerization of the CARs. The disclosure also provides compositions and methods useful for producing such molecules, as well as methods for the detection and treatment of health conditions, such as proliferative diseases (e.g., cancer).
    Type: Application
    Filed: September 9, 2021
    Publication date: October 26, 2023
    Inventors: Yannick MULLER, Jeffrey A. BLUESTONE, Qizhi TANG
  • Publication number: 20230340106
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Application
    Filed: September 16, 2022
    Publication date: October 26, 2023
    Applicants: Pfizer Inc., The Regents of the University of California, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Publication number: 20230312673
    Abstract: This disclosure relates to chimeric receptors (CRs) and their signaling components for the regulation of an immune response. Also provided are nucleic acids encoding the disclosed CRs, recombinant immune cells expressing the same, and pharmaceutical compositions containing the disclosed nucleic acids and/or recombinant cells.
    Type: Application
    Filed: September 1, 2021
    Publication date: October 5, 2023
    Inventors: Kole T. ROYBAL, Daniel B. GOODMAN, Camillia AZIMI, Alexander MARSON, Jeffrey A. BLUESTONE
  • Publication number: 20230280341
    Abstract: The invention provides methods of isolating CD 127lo/? immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.
    Type: Application
    Filed: July 7, 2022
    Publication date: September 7, 2023
    Applicant: The Regents of the University of California
    Inventors: Jeffrey A. Bluestone, Weihong Liu, Amy Putnam
  • Patent number: 11459385
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: October 4, 2022
    Assignees: The Regents of the University of California, The Board of Trustees of the Leland Stanford Junior University, Pfizer, Inc.
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Publication number: 20220281943
    Abstract: Chimeric antigen receptor (CAR)-expressing Tregs specifically target modified protein or proteins present in the extra cellular matrix of an inflammatory lesion of patients to induce a localized and effective immunosuppressive response.
    Type: Application
    Filed: August 10, 2020
    Publication date: September 8, 2022
    Inventors: Jeffrey A. Bluestone, Caroline Raffin
  • Patent number: 11435349
    Abstract: The invention provides methods of isolating CD127lo/? immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: September 6, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jeffrey A. Bluestone, Weihong Liu, Amy Putnam
  • Publication number: 20210340496
    Abstract: Provided herein are compositions and methods for modifying regulatory T cells. The inventors have identified nuclear factors that influence expression of Foxp3, a key transcriptional regulator of Treg cells. Treg cells can be modified by inhibiting and/or overexpressing one or more of these nuclear factors to produce stabilized Treg cells or destabilized Treg cells.
    Type: Application
    Filed: October 10, 2019
    Publication date: November 4, 2021
    Applicant: The Regents of the University of California
    Inventors: Alexander Marson, Jessica T. Cortez, Jeffrey A. Bluestone, Eric Shifrut, Frederic Van Gool
  • Publication number: 20210147841
    Abstract: The disclosure features methods directed to modifying regulatory T (Treg) cell stability by inhibiting the expression of one or more transcription factors and/or inhibiting one or more genes or gene products regulated by the transcription factors. The disclosure also features compositions comprising the Treg cells having modified stability.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 20, 2021
    Inventors: Alexander Marson, Jeffrey A. Bluestone, Kathrin Schumann
  • Publication number: 20210061902
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Application
    Filed: July 9, 2020
    Publication date: March 4, 2021
    Inventors: Isaac J. RONDON, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Publication number: 20210032308
    Abstract: The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.
    Type: Application
    Filed: September 28, 2020
    Publication date: February 4, 2021
    Inventors: Natasha Kay CRELLIN, Lauren Kate ELY, Jason Robles REYES, Chia Chi HO, Jeffrey A. BLUESTONE, Eleonora TROTTA, Qizhi TANG
  • Publication number: 20210017248
    Abstract: Chimeric antigen receptor (CAR)-expressing T regulatory cells (Tregs) include intracellular co-stimulatory or inhibitory domains based on the biology, functions and activities of Tregs. The co-stimulatory or inhibitory domains modulate the Treg response, thereby, activating or suppressing an effector T cell (Teff) immune response to specific antigens.
    Type: Application
    Filed: March 15, 2019
    Publication date: January 21, 2021
    Inventors: Jeffrey A. Bluestone, Qizhi Tang, Leonardo M.R. Ferreira
  • Publication number: 20200399355
    Abstract: Chimeric antigen receptor (CAR)-expressing Tregs specifically target an antigen present in the joint of RA patients to induce a localized and effective immunosuppressive response.
    Type: Application
    Filed: February 11, 2019
    Publication date: December 24, 2020
    Inventors: JEFFREY A. BLUESTONE, CAROLINE RAFFIN
  • Publication number: 20200360446
    Abstract: Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.
    Type: Application
    Filed: December 12, 2018
    Publication date: November 19, 2020
    Inventors: Casey WARD, Qizhi TANG, Peter STOCK, Gaetano FALEO, Gopika NAIR, Mathias HEBROK, Wenhan CHANG, Linda Thuy VO, Jeffrey A. BLUESTONE, Eleonora DE KLERK
  • Patent number: 10738113
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: August 11, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, PFIZER INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia